These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17080767)

  • 21. Monitoring event times in early phase clinical trials: some practical issues.
    Thall PF; Wooten LH; Tannir NM
    Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II trials: time for a new era in clinical trial design.
    Mandrekar SJ; Sargent DJ
    J Thorac Oncol; 2010 Jul; 5(7):932-4. PubMed ID: 20581575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design issues of randomized phase II trials and a proposal for phase II screening trials.
    Rubinstein LV; Korn EL; Freidlin B; Hunsberger S; Ivy SP; Smith MA
    J Clin Oncol; 2005 Oct; 23(28):7199-206. PubMed ID: 16192604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
    Thall PF; Simon RM; Estey EH
    J Clin Oncol; 1996 Jan; 14(1):296-303. PubMed ID: 8558211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bayesian adaptive design for biomarker trials with linked treatments.
    Wason JM; Abraham JE; Baird RD; Gournaris I; Vallier AL; Brenton JD; Earl HM; Mander AP
    Br J Cancer; 2015 Sep; 113(5):699-705. PubMed ID: 26263479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New designs for phase 2 clinical trials.
    Estey EH; Thall PF
    Blood; 2003 Jul; 102(2):442-8. PubMed ID: 12560224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.
    Thall PF; Sung HG
    Stat Med; 1998 Jul; 17(14):1563-80. PubMed ID: 9699230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.
    Hoering A; Mitchell A; LeBlanc M; Crowley J
    Clin Trials; 2013; 10(3):422-9. PubMed ID: 23529697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian monitoring of phase II trials in cancer chemoprevention.
    Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ
    J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.
    Zohar S; Teramukai S; Zhou Y
    Contemp Clin Trials; 2008 Jul; 29(4):608-16. PubMed ID: 18201945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous Bayesian adaptive randomization based on event times with covariates.
    Cheung YK; Inoue LY; Wathen JK; Thall PF
    Stat Med; 2006 Jan; 25(1):55-70. PubMed ID: 16025549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
    Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
    Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian randomized clinical trials: From fixed to adaptive design.
    Yin G; Lam CK; Shi H
    Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.